论文部分内容阅读
华北制药股份有限公司:你公司报送的配股申报材料收悉。根据河北省证券监督管理委员会《关于同意华北制药股份有限公司增资配股申报材料的报告》(冀证监[1998]28号)及《华北制药股份有限公司1998年临时股东大会决议》,经审核,现批复如下:一、同意你公司向全体股东配售170,196,256股普通股。其中向国家股股东配售
North China Pharmaceutical Co., Ltd.: Your company submitted the placement declaration materials received. According to the “Report on Consenting Capital Increase and Share Application of North China Pharmaceutical Co., Ltd.” (Ji Zheng Jian [1998] No. 28) and the “Resolution of Extraordinary Shareholders’ General Meeting of North China Pharmaceutical Co., Ltd. in 1998”, upon examination and approval, The following is approved: I. It is agreed that you should place 170,196,256 ordinary shares to all shareholders. Among them, the allotment of shares to state shareholders